Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.

Chao, J; Buxo, E; Cervantes, A; Dayyani, F; Lima, CMSR; Greil, R; Van Laarhoven, HWM; Lorenzen, S; Heinemann, V; Kischel, R; Shitara, K; Lordick, F